U.S. Markets open in 8 hrs 49 mins

PolyPid Ltd. (PYPD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.4985-0.0146 (-2.85%)
At close: 03:58PM EDT
0.5234 +0.02 (+4.99%)
After hours: 05:10PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5131
Bid0.0000 x 2200
Ask0.0000 x 1800
Day's Range0.4976 - 0.5220
52 Week Range0.4976 - 6.9000
Avg. Volume404,676
Market Cap9.798M
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-2.1730
Earnings DateMay 09, 2023 - May 15, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.38
  • GlobeNewswire

    PolyPid to Present at the Barclays Global Healthcare Conference

    PETACH TIKVA, Israel, March 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 14-16, 2023. Barclays Global Investor Conference: Presentation Date: Tuesday, March 14, 2023Presentation Time:4:35 PM Eastern Time Investors interested in meeting with PolyPid during th

  • Insider Monkey

    PolyPid Ltd. (NASDAQ:PYPD) Q4 2022 Earnings Call Transcript

    PolyPid Ltd. (NASDAQ:PYPD) Q4 2022 Earnings Call Transcript February 8, 2023 Operator: Greetings, and welcome to the PolyPid Fourth Quarter and Full Year 2022 Conference Call. . As a reminder, this call is recorded. And I would now like to introduce your host for today’s conference, Brian Ritchie from LifeSci Advisors. Mr. Ritchie, you may […]

  • GlobeNewswire

    PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

    Following Positive Communication with the FDA, Regulatory Pathway Clarified for D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections Company Expects to Resume Patient Recruitment in Q2 2023 into Ongoing SHIELD II Trial, which will be Enriched with Approximately 550 Additional Patients to Complete Clinical Testing for Potential NDA Top-line Results from SHIELD II Trial Anticipated mid-2024 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 08, 2023 (